The 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons brought together medical experts, researchers, and healthcare professionals in New Orleans from March 2 to March 6, 2026. Among the many clinical discussions and research presentations, one topic that drew significant attention was the impact of GLP-1 receptor agonists on musculoskeletal health.
These medications have become widely used in recent years for treating patients with obesity and Type 2 Diabetes. While they offer strong benefits for blood sugar control and weight management, new studies presented at the meeting suggest that the long-term effects of these drugs on bone and joint health may be more complex than previously understood.
Researchers presented findings that show potential short-term benefits after orthopaedic surgery for patients using GLP-1 medications. However, the same research also suggests a possible increase in long-term risks such as Osteoporosis, Gout, and Osteomalacia. These results highlight the need for ongoing research as the popularity of these medications continues to grow worldwide.
GLP-1 receptor agonists have rapidly expanded in use over the past decade. Drugs in this class, including Semaglutide, are widely prescribed for improving glycemic control in diabetes and supporting weight loss in patients with obesity.
These medications work by mimicking a natural hormone that helps regulate blood sugar, appetite, and digestion. As a result, they have shown strong benefits in several areas of metabolic health, including:
Because of these benefits, GLP-1 medications have become increasingly common in patients who may also require orthopaedic procedures. Obesity and joint degeneration often overlap, making it important for surgeons and clinicians to understand how these medications affect bone health and surgical recovery.
Researchers noted that the rapid adoption of GLP-1 therapies means long-term data is only now becoming available. Five-year and ten-year follow-up studies are beginning to provide a clearer picture of how these drugs may influence the musculoskeletal system.
One study presented at the meeting explored how GLP-1 medications affect recovery after common orthopaedic procedures.
Researchers conducted a retrospective cohort study using a national claims database covering surgeries performed between 2010 and 2023. The analysis focused on patients with obesity who underwent several major orthopaedic procedures, including:
The research team tracked trends in GLP-1 medication use before surgery and examined how these drugs influenced postoperative outcomes.
The study identified a steady increase in GLP-1 medication use among orthopaedic surgery patients, with a particularly sharp rise beginning in 2019.
Important findings included:
Lower emergency department visits after surgery
Patients using GLP-1 medications showed significantly lower rates of postoperative emergency department visits across multiple orthopaedic procedures.
Reduced surgical site infection risk
For individuals undergoing total knee or total hip replacement, GLP-1 users experienced lower rates of surgical site infections.
Mixed results for revision surgery
Revision rates were lower among patients undergoing knee replacement but higher among those who had carpal tunnel release procedures.
Overall, the research suggests that GLP-1 therapy may contribute to improved short-term recovery outcomes following certain orthopaedic surgeries.
However, researchers emphasized that further investigation is needed to fully understand how these medications interact with surgical healing processes.
Another major study presented at the conference focused on the potential long-term musculoskeletal effects of GLP-1 receptor agonists.
This research evaluated patients with Type 2 diabetes and obesity who were treated with GLP-1 medications. Investigators used a large multi-institutional electronic health record database to compare outcomes between GLP-1 users and matched control patients.
After adjusting for factors such as age, gender, body mass index, tobacco use, and other health conditions, the final analysis included more than 73,000 patients with balanced baseline characteristics.
After five years of follow-up, researchers identified several statistically significant differences between the two groups.
Osteoporosis risk increased
Patients using GLP-1 medications had a higher rate of osteoporosis compared with non-users. The incidence reached 4.1 percent among GLP-1 users compared with 3.2 percent in the control group.
Higher gout incidence
Gout occurred in 7.4 percent of GLP-1 users compared with 6.6 percent in patients who did not use the medications.
Marked increase in osteomalacia risk
The most notable increase was observed for osteomalacia, a condition characterized by softening of the bones due to impaired mineralization.
Although the overall incidence remained relatively low, the relative risk increase was significant.
Researchers emphasized that these results do not necessarily mean the medications directly cause these conditions. Instead, they highlight potential associations that should be monitored carefully in clinical practice.
As GLP-1 therapies continue to expand in use, clinicians are being encouraged to monitor bone health more closely in patients who may be at higher risk.
Certain individuals may already be vulnerable to musculoskeletal conditions, including:
In these populations, routine monitoring for bone density changes and metabolic complications may help identify potential issues earlier.
Healthcare providers may consider tools such as bone density scans, nutritional assessment, and vitamin monitoring when managing long-term GLP-1 therapy.
The findings presented at the AAOS meeting highlight an important emerging area of research. As medications like semaglutide become more widely used, their broader effects on the body must be understood beyond metabolic benefits alone.
Researchers stress that GLP-1 therapies remain highly effective treatments for diabetes and obesity. However, long-term data is still evolving, especially regarding bone metabolism and musculoskeletal outcomes.
Future studies are expected to focus on:
These insights may help clinicians develop more comprehensive treatment plans that balance metabolic benefits with musculoskeletal health considerations.
Research presented at the 2026 annual meeting of the American Academy of Orthopaedic Surgeons highlights both the potential advantages and possible risks associated with GLP-1 receptor agonists.
On one hand, patients using these medications may experience improved short-term outcomes after certain orthopaedic procedures. On the other hand, emerging data suggests a potential increase in long-term risks for conditions such as osteoporosis, gout, and osteomalacia.
As GLP-1 medications continue to transform the treatment landscape for obesity and diabetes, healthcare professionals will need to take a balanced and informed approach to patient management.
Monitoring bone health, conducting further research, and evaluating long-term outcomes will be essential to ensuring that patients receive the maximum benefits of these therapies while minimizing potential complications.
American Academy of Orthopaedic Surgeons. Research presented at the AAOS 2026 Annual Meeting in New Orleans, March 2–6, 2026. Official AAOS clinical news release on GLP-1 receptor agonists and musculoskeletal health.
This article is intended for informational and educational purposes only. It does not provide medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals for medical guidance regarding medications, surgery, or health conditions. The findings summarized in this article are based on research presented at a scientific conference and may require further peer-reviewed validation before influencing clinical practice.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.